贝利尤单抗联合环孢素治疗难治性系统性红斑狼疮继发免疫性血小板减少1例并文献复习

doi:10.3969/j.issn.1004-583X.2022.06.012

临床荟萃 ›› 2022, Vol. 37 ›› Issue (6): 544-547.doi: 10.3969/j.issn.1004-583X.2022.06.012

贝利尤单抗联合环孢素治疗难治性系统性红斑狼疮继发免疫性血小板减少1例并文献复习

秦梅杰¹, 田茂露², 杨宇齐², 查艳², 袁静²()

1.遵义医科大学,贵州遵义 563003
2.贵州省人民医院肾内科, 贵州贵阳 550002

收稿日期:2022-04-07 出版日期:2022-06-20 发布日期:2022-08-05
通讯作者: 袁静 E-mail:yuanjinger@126.com
基金资助:
贵州省科学技术基金-长链非编码RNA Cdat 1通过调控CaMKⅡ/AMPK/NF-kB信号通路影响糖尿病肾病慢性纤维化(黔科合基础[2019]1194号);贵州省卫健委科学技术基金-长链非编码RNA Cdat 1在糖尿病肾病中的作用及其机制研究(gzwjkj2019-1-107)

Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review

Qin Meijie¹, Tian Maolu², Yang Yuqi², Zha Yan², Yuan Jing²()

1. Zunyi Medical University, Zunyi 563003, China
2. Department of Nephrology,Guizhou Provincial People’s Hospital, Guiyang 550002, China

Received:2022-04-07 Online:2022-06-20 Published:2022-08-05
Contact: Yuan Jing E-mail:yuanjinger@126.com

摘要/Abstract

摘要：

目的探讨贝利尤单抗治疗难治性系统性红斑狼疮(systemic lupus erythematosus,SLE)合并顽固性血液系统损害的疗效。方法回顾性分析贵州省人民医院收治的1例以顽固性血液系统损害为主要表现的SLE病例的诊治过程。结果患者为青年女性,SLE病史1年余,因皮下瘀斑伴腹痛10天入院,住院后明确诊断SLE合并难治性血液系统损害,在环孢素等基础治疗上加用贝利尤单抗维持治疗后,患者病情明显改善,且未见不良反应。随访1年余,患者激素用量已减至最低维持量,无复发。结论贝利尤单抗联合环孢素治疗为难治性SLE继发免疫性血小板减少的治疗提供了新选择,更多的临床应用证据有待长期的大样本病例研究观察、评估。

关键词: 红斑狼疮,系统性, 紫癜,血小板减少性,特发性, 抗体,单克隆

Abstract:

Objective To explore the effects of belimumab on systemic lupus erythematosus (SLE) complicated with refractory hematological damage. Methods A SLE patient mainly featured with refractory hematological damage admitted to Guizhou Provincial People's Hospital was retrospectively analyzed. Results The female patient with more than 1 year history of SLE was admitted to hospital for sub dermal ecchymosis complicated with abdominal pain lasting 10 days, was clearly diagnosed as SLE with refractory blood system damage after hospitalization. The patient's condition was significantly improved without adverse reactions after maintenance therapy with belimumab in addition to basic treatment including cyclosporine. The patient was followed up for more than 1 year, the glucocorticoid dosage was minimized, and no recurrence of disease was found. Conclusion Combination of belimumab with cyclosporine in the treatment of refractory SLE secondary immune thrombocytopenia provides a new treatment option, and more clinical efficacy remains to be observed and evaluated in the long term.

Key words: lupus erythematosus,systemic, purpura,thrombocytopenia,idiopathic, antibodies,monoclonal

中图分类号:

R593.241

秦梅杰, 田茂露, 杨宇齐, 查艳, 袁静. 贝利尤单抗联合环孢素治疗难治性系统性红斑狼疮继发免疫性血小板减少1例并文献复习[J]. 临床荟萃, 2022, 37(6): 544-547.

Qin Meijie, Tian Maolu, Yang Yuqi, Zha Yan, Yuan Jing. Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review[J]. Clinical Focus, 2022, 37(6): 544-547.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.06.012

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I6/544

图/表 2

参考文献 17

[1]	Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus[J]. Lupus Sci Med, 2015, 2(1):e000078. doi: 10.1136/lupus-2014-000078 URL
[2]	Audia S, Mahevas M, Samson M, et al. Pathogenesisi of im-mune thrombocytopenia[J]. Autoimmun Rev, 2017, 16(6):620-632. doi: 10.1016/j.autrev.2017.04.012 URL
[3]	Baroni Pietto MC, Lev PR, Glembotsky AC, et al. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus[J]. Platelets, 2021, 21:1-12. doi: 10.3109/09537100903391015 URL
[4]	龙现明, 蔡成森. 系统性红斑狼疮继发难治性血小板减少的临床特征分析[J]. 中华风湿病学杂志, 2020, 24(3):203-205.
[5]	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3):172-185.
[6]	Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus[J]. Rheumatol Int, 2020, 40(10):1717-1724. doi: 10.1007/s00296-020-04668-4 pmid: 32797277
[7]	Yudhishdran J, Sivakumar J, Navinan MR, et al. Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: A case report[J]. J Med Case Rep, 2021, 15(1):339. doi: 10.1186/s13256-021-02950-y URL
[8]	Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell deple-tion for autoimmune thrombocytopenia and autoimmune hemolyticanemia in pediatric systemic lupus erythematosus[J]. Pediatrics, 2009, 123(1):159-163.
[9]	Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1):3-19. doi: 10.1080/08830185.2016.1276903 URL
[10]	Depascale R, Gatto M, Zen M, et al. Belimumab: A step forward in the treatment of systemic lupus erythematosus[J]. Expert Opin Biol Ther, 2021, 21(5):563-573. doi: 10.1080/14712598.2021.1895744 URL
[11]	Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol[J]. BMJ Open, 2019, 9(3):e025687. doi: 10.1136/bmjopen-2018-025687 URL
[12]	Xu P, Shao X, Ou Y, et al. Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction[J]. Clin Transl Immunol, 2022, 11: e1399.
[13]	Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2):403-413. doi: 10.1016/j.kint.2021.08.027 URL
[14]	Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis[J]. Ann Rheum Dis, 2019, 78: 372-379. doi: 10.1136/annrheumdis-2018-214043 pmid: 30610066
[15]	Sheikh SZ, Scheinberg MA, Cheng-Chung Wei, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial[J]. Lancet Rheumatol, 2021, 3: e122-e 130.
[16]	Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results[J]. Nephrol Dial Transplan, 2021, 36(8):1474-1483. doi: 10.1093/ndt/gfaa117 URL
[17]	冯秀媛, 闫慧明, 王永福, 等. 系统性红斑狼疮血液系统受累的相关性分析[J]. 临床荟萃, 2011, 26(23): 2086-2088.

贝利尤单抗联合环孢素治疗难治性系统性红斑狼疮继发免疫性血小板减少1例并文献复习

Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高原;孟庆华;刘海霞;朱跃科. 以肝功能异常为首发症状就诊的系统性红斑狼疮15例分析[J]. 临床荟萃, 2015, 30(7): 806-810.
[2]	黄志芳;李新伦;李红霞;伦立德. 静脉注射免疫球蛋白对重症系统性红斑狼疮的疗效及安全性[J]. 临床荟萃, 2014, 29(11): 1243-1245.
[3]	姜立萍;黄雯;李秀季;梁巧静;张国娟. 以视网膜病变为首发表现的系统性红斑狼疮1例[J]. 临床荟萃, 2014, 29(9): 1066-1067.
[4]	李宏博;张景坤;吴超;王冀;张玉军;高丽霞. 高迁移率族蛋白1、Toll 样受体4和血管细胞黏附因子1与狼疮性肾炎血脂异常的关系[J]. 临床荟萃, 2014, 29(8): 891-895.
[5]	赵凌杰;邱艳;蔡辉. 以腹痛为首发表现并发假性肠梗阻的系统性红斑狼疮1例并文献复习[J]. 临床荟萃, 2013, 28(10): 1179-1181.
[6]	王增玲;邢广群;李春梅. 系统性红斑狼疮患者血清肽酰基精氨酸脱亚胺酶4水平及意义[J]. 临床荟萃, 2013, 28(5): 515-518.
[7]	许小玲;俞烜华;李忆农. 系统性红斑狼疮中B细胞活化因子、干扰素α的表达及临床意义[J]. 临床荟萃, 2013, 28(5): 522-524532.
[8]	许超;张芳;耿洁;杨文彦. 系统性红斑狼疮伴重度肝功能损害1例[J]. 临床荟萃, 2012, 27(19): 1741-1742.
[9]	白润涛;葛朝莉;冯宏业;韩漫夫. 中枢神经系统损害为首发症状的系统性红斑狼疮临床分析[J]. 临床荟萃, 2012, 27(15): 1302-1305.
[10]	徐国栋;马志俊;孙志坚. 系统性红斑狼疮患者血清白细胞介素2、6、10水平的变化及临床意义[J]. 临床荟萃, 2012, 27(6): 527-528.
[11]	王子威. 神经精神性狼疮伴蛛网膜下腔出血1例并文献复习[J]. 临床荟萃, 2011, 26(5): 435-436.
[12]	俞烜华;李忆农. 系统性红斑狼疮心脏受累85例超声心动图的临床特征分析[J]. 临床荟萃, 2010, 25(13): 1119-1122.
[13]	赵敏;王新良. 肾活检确诊系统性红斑狼疮1例[J]. 临床荟萃, 2010, 25(13): 1175-0.
[14]	王芬;徐建华;徐胜前;刘爽;连莉;陈珊宇. 妊娠前应用免疫抑制剂对系统性红斑狼疮患者妊娠结局的影响[J]. 临床荟萃, 2010, 25(8): 699-701.
[15]	田溢卿;宁晓然;阎永龙;孙丽君;张风肖;李芳. 糖皮质激素对非绝经期女性系统性红斑狼疮患者骨代谢指标和白细胞介素18的影响[J]. 临床荟萃, 2009, 24(16): 1442-1443.